Tech Transfer Tidbits

Premium

Merck, Medarex, and UMass Med's MBL Strike Deal for C. Difficile mAbs

Merck, Medarex, and Massachusetts Biologic Laboratories of the University of Massachusetts Medical School said this week that they have entered into a licensing agreement for a pair of human monoclonal antibodies for treating Clostridium difficile infections.

Under the terms of the agreement, Merck gains exclusive worldwide rights to develop and commercialize the mAb combination CDA-1 and CDB-1, which were co-developed by Medarex and MBL.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: method to detect single-nucleotide and copy-number alterations in single cells from archival tissue, and more.

China has announced new rules governing the use of stem cell treatments, Nature News reports.

Wired's Sarah Zhang expresses frustration as a microbiome study of homes uncovers expected bacteria.

A database containing genome sequences from strains of foodborne pathogens may enable regulators and companies to quickly identify outbreak sources, Reuters reports.

Oct
15
Sponsored by
Parabase

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit.